EP2723896A2 - Mutations observées en cas de tumeurs pancréatiques - Google Patents

Mutations observées en cas de tumeurs pancréatiques

Info

Publication number
EP2723896A2
EP2723896A2 EP12802288.6A EP12802288A EP2723896A2 EP 2723896 A2 EP2723896 A2 EP 2723896A2 EP 12802288 A EP12802288 A EP 12802288A EP 2723896 A2 EP2723896 A2 EP 2723896A2
Authority
EP
European Patent Office
Prior art keywords
mutation
gnas
mutations
pancreatic
ipmn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12802288.6A
Other languages
German (de)
English (en)
Other versions
EP2723896A4 (fr
EP2723896B1 (fr
Inventor
Bert Vogelstein
Kenneth W. Kinzler
Jian Wu
Luis Diaz
Nickolas Papadopoulos
Hanno MATTHAEI
Ralph Hruban
Anirban Maitra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP2723896A2 publication Critical patent/EP2723896A2/fr
Publication of EP2723896A4 publication Critical patent/EP2723896A4/fr
Application granted granted Critical
Publication of EP2723896B1 publication Critical patent/EP2723896B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • This invention is related to the area of cancer markers. In particular, it relates to markers that are helpful for diagnosis, prognosis, and theranostics.
  • Pancreatic cysts occur in more than 20% of patients evaluated at autopsy and in 2.4% to 13% of patients studied by abdominal imaging (CT scan or MRI) for reasons unrelated to pancreatic pathology (1-4).
  • CT scan or MRI abdominal imaging
  • pancreatic pathology 1-4
  • CT scan or MRI pancreatic pathology
  • Serous cystic adenomas account for -10% of surgically resected cystic lesions of the pancreas (8, 9). These cysts are thought to be totally benign with essentially no likelihood of becoming invasive (that is, of becoming PDA).
  • Intraductal papillary mucinous neoplasms IPMNs
  • Those in the main ducts are most aggressive, as -45% are found to have progressed to invasive carcinoma at the time of surgical resection (10).
  • IPMNs can also be classified into three histologic subtypes - intestinal, pancreatobiliary, and gastric - based on the resemblance of their epithelial cells to those of the corresponding normal tissues.
  • MCNs Mucinous Cystic Neoplasms
  • the average age of women with MCNs is more than 20 years less than that of patients with either SCAs or IPMNs (12).
  • the remainder of surgically resected cystic lesions of the pancreas are a heterogeneous group of retention cysts, congenital cysts, and other rarer lesions.
  • PDAs can be divided into two types: those that develop in the absence of cystic lesions and those that develop from a cystic lesion.
  • the prognoses of patients with PDAs developed from IPMNs are different from those in patients with PDAs that develops in the apparent absence of IPMNs (11, 13).
  • the survival of patients with surgically resected PDAs associated with IPMNs is as high as 45% at 5 years (11, 13). In contrast, survival is very rare in other PDA patients (14). While some of the difference in survival is due to differences in stage at diagnosis, investigators have suggested that "carcinoma arising in IPMNs is a different disease" from the more common type of PDA that develops without any associated cystic precursor (75).
  • a method distinguishes between pancreatic serous cystic adenomas (SCA) and pancreatic intraductal papillary mucinous neoplasms (IPMN).
  • SCA pancreatic serous cystic adenomas
  • IPMN pancreatic intraductal papillary mucinous neoplasms
  • a method distinguishes between pancreatic mucinous cystic neoplasm (MCN) and pancreatic intraductal papillary mucinous neoplasms (IPMN).
  • MCN pancreatic mucinous cystic neoplasm
  • IPMN pancreatic intraductal papillary mucinous neoplasms
  • a method identifies pancreatic ductal adenocarcinomas (PDA) derived from pancreatic intraductal papillary mucinous neoplasms (IPMN).
  • PDA pancreatic ductal adenocarcinomas
  • IPMN pancreatic intraductal papillary mucinous neoplasms
  • a method detects a pancreatic intraductal papillary mucinous neoplasms (IPMN).
  • IPMN pancreatic intraductal papillary mucinous neoplasms
  • Fig. 1 provides a schematic of a capture strategy. Overlapping oligonucleotides flanked by universal sequences complimentary to the 169 genes listed in Fig. 5 (Table SI) were synthesized on an array. The oligonucleotides were cleaved off the array, amplified by PCR with universal primers, ligated into concatamers and amplified in an isothermal reaction. They were then bound to nitrocellulose filters and used as bait for capturing the desired fragments. An Illumina library was constructed from the sample DNA. The library was denatured and hybridized to the probes immobilized on nitrocellulose. The captured fragments were eluted, PCR amplified and sequenced on an Illumina GAIIX instrument.
  • Figs. 2A-2B show a ligation assays used to assess KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) and GNAS (guanine nucleotide binding protein (G protein), alpha stimulating activity polypeptide 1) mutations.
  • Fig. 2 A Schematic of the ligation assay. Oligonucleotide probes complementary to either the WT or mutant sequences were incubated with a PCR product containing the sequence of interest. The WT- and mutant-specific probes were labeled with the fluorescent dyes 6-FAM and HEX, respectively, and the WT-specific probe was 11 bases longer than the mutant-specific probe.
  • Fig. 2 B Examples of the results obtained with the ligation assay in the indicated patients. Templates were derived from DNA of normal duodenum or IPMN tissue. Each lane represents the results of ligation of one of four independent PCR products, each containing 200 template molecules. The probe in the left panel was specific to the GNAS R201H mutation and the probe on the right panel was specific for the GNAS R201C mutation.
  • Fig. 3 shows BEAMing assays used to quantify mutant representation.
  • PCR was used to amplify KRAS or GNAS sequences containing the region of interest (KRAS codon 12 and GNAS codon 201).
  • the PCR-products were then used as templates for BEAMing, in which each template was converted to a bead containing thousands of identical copies of the templates (34).
  • the beads were analyzed by flow cytometry. Scatter plots are shown for templates derived from the DNA of IPMN 130 or from normal spleen.
  • Beads containing the WT or mutant sequences are widely separated in the scatter plots, and the fraction of mutant-containing beads are indicated. Beads whose fluorescence spectra lie between the WT and mutant-containing beads result from inclusion of both WT and mutant templates in the aqueous nanocompartments of the emulsion PCR. .
  • FIGs. 4A-4C show IPMN morphologies.
  • FIG. 4A H&E-stained section of a formalin- fixed, paraffin embedded sample (shows two apparently independent IPMNs with distinct morphologies located close to one another.
  • FIG. 4B H&E stained section of a different, typical IPMN
  • Fig. 4C Same IPMN as in Fig. 4B after microdissection of the cyst wall.
  • Fig. 7. (Table S3.) Characteristics of patients with cyst types other than IPMN, including GNAS and KRAS mutation status.
  • Test samples can be from any appropriate source in the patient's body that will have nucleic acids from a pancreatic lesion that can be collected and tested. In some cases the nucleic acids will be amplified prior to testing. Suitable test samples may be obtained from pancreatic cyst fluid, pancreatic cyst wall tissue, pancreatic ductal adenocarcinoma tissue, blood, stool, and pancreatic juice. The samples may be collected using any means conventional in the art, including from surgical samples, from biopsy samples, from endoscopic ultrasound (EUS), phlebotomy, etc. Obtaining the samples may be performed by the same person or a different person that conducts the subsequent analysis. Samples may be stored and/or transferred after collection and before analysis. Samples may be fractionated, treated, purified, enriched, prior to assay.
  • EUS endoscopic ultrasound
  • Any means of testing for a mutation in codon 201 of GNAS or codon 12 of KRAS may be used. Mutations may be detected by sequencing, by hybridization assay, by ligation assay, etc. Because the locations of the relevant mutations are defined, specific assays which focus on the identified locations may be used. Identifying a mutation as somatic can be accomplished by comparing a test sample to a non-neoplastic sample, either from the same patient or from a healthy individual.
  • the wild type codon 201 encodes an arginine. Mutants may be any other codon, in particular one coding for histidine or for cysteine.
  • a wild type KRAS codon 12 encodes a glycine, but it may be mutated to, for example, encode for aspartic acid, valine, or arginine.
  • the defined locations of the mutations permit focused assays limited to an exon, domain, or codon. Any assay that is performed on a test sample involves a transformation, for example, a chemical or physical change or act. Assays and determinations are not performed merely by a perceptual or cognitive process in the body of a person.
  • Probes and/or primers may contain the wild-type or a mutant sequence. These can be used in a variety of different assays, as will be convenient for the particular situation. Selection of assays may be based on cost, facilities, equipment, electricity availability, speed, reproducibility, compatibility with other assays, invasiveness of sample collection, sample preparation, etc.
  • any of the assay results may be recorded or communicated, as a positive act or step.
  • Communication of an assay result, diagnosis, identification, or prognosis may be, for example, orally between two people, in writing, whether on paper or digital media, by audio recording, into a medical chart or record, to a second health professional, or to a patient.
  • the results and/or conclusions and/or recommendations based on the results may be in a natural language or in a machine or other code.
  • Such records are kept in a confidential manner to protect the private information of the patient.
  • Collections of probes, primers, control samples, and reagents can be assembled into a kit for use in the methods.
  • the reagents can be packaged with instructions, or directions to an address or phone number from which to obtain instructions.
  • An electronic storage medium may be included in the kit, whether for instructional purposes or for recordation of results, or as means for controlling assays and data collection.
  • Control samples can be obtained from the same patient from a tissue that is not apparently diseased. Alternatively, control samples can be obtained from a healthy individual or a population of apparently healthy individuals. Control samples may be from the same type of tissue or from a different type of tissue than the test sample.
  • protein based assays can be performed.
  • antibodies can be used which are specific for particular alternative residues in the GNAS protein at residue 201.
  • Antibodies for wild type and or various mutant residues can be used. They can, for example, be differentially labeled. They can be used, for example, in separate assays and be similarly labeled or detected. Assays can also be based on differential protein activities of mutant and wild-type forms. Additionally, analyte levels can be assayed. High adenyl cyclase activity and cAMP levels Intraductal papillary mucinous neoplasms are characteristic of cells with GNAS mutations in codon 201.
  • cyst fluid obtained through EUS, though safe, is an invasive procedure. Complications include bleeding, infection, and pancreatitis, are reversible, and are generally observed in ⁇ 1% of patients (reviewed in(5i)). Second, neither KRAS nor GNAS mutations can distinguish high grade or invasive from low grade IPMNs.
  • pancreatic cyst fluid samples from pancreatectomy specimens and/or fresh frozen tumor tissues were available for molecular analysis.
  • Relevant demographic, clinicopathologic data were obtained from prospectively maintained clinical databases and correlated with mutational status.
  • Pancreatic cyst fluids were harvested in the Surgical Pathology suite from surgically resected pancreatectomy specimens with a sterile syringe. Aspirated fluids were stored at -80°C within 30 min of resection. Fresh-frozen tissue specimens of surgically resected cystic neoplasms of the pancreas were obtained through a prospectively maintained Johns Hopkins Surgical Pathology Tumor Bank. These lesions as well as normal tissues were macrodissected using serial frozen sections to guide the trimming of OCT embedded tissue blocks to obtain a minimum neoplastic cellularity of 80%.
  • Formalin-fixed and paraffin-embedded archival tissues from surgically resected pancreata were sectioned at 6 ⁇ , stained with hematoxylin and eosin, and dissected with a sterile needle on a SMZ1500 stereomicroscope (Nikon). An estimated 5,000-10,000 cells were microdissected from each lesion. Lesions were classified as IPMNs, MCNs, or SCAs using standard criteria (53). IPMNs were subtyped by internationally accepted criteria (54).
  • DNA was purified from frozen cyst walls using an AUPrep kit (Qiagen) and from forrmalin-fixed, paraffin-embedded sections using the QIAamp DNA FFPE tissue kit (Qiagen) according to the manufacturer's instructions. DNA was purified from 250 ⁇ , of cyst fluid by adding 3 ml RLTM buffer (Qiagen) and then binding to an AUPrep DNA column (Qiagen) following the manufacturer's protocol. DNA was quantified in all cases with qPCR, employing primers and conditions as described (55).
  • Cyst fluid DNA was first quantified through real-time PCR using primers specific for repeated sequences in DNA (LINE) as described (56). A minimum of 100 ng DNA from cyst fluid was used to make Illumina libraries according to manufacturer's protocol with the exception that the amount of adapters was decreased in proportional fashion when a lower amount of template DNA was used. The number of PCR cycles used to amplify the library after ligation of adapters was varied to ensure a yield of ⁇ 5 ug of the final library product for capture.
  • the targeted region included all of the 3386 exons of 169 cancer related genes and was enriched with custom-made oligonucleotide probes.
  • the design of each oligonucleotide was as follows: 5'-TCCCGCGACGAC - 36 bases from the genomic region of interest - GCTGGAGTCGCG - 3' (SEQ ID NO: 1). Probes were designed to capture both the plus and the minus strand of the DNA and had a 33 -base overlap. The probes were custom- synthesized by Agilent Technology on a chip. The oligonucleotides were cleaved from the chip by treatment for five hours with 3 ml 35% ammonium hydroxide at room temperate.
  • the solution was transferred to two 2-ml tubes, dried under vacuum, and re- dissolved in 400 ul RNase and DNase free water. Five ul of the solution were used for PCR amplification with primers complementary to the 12 base sequence common to all probes: 5-TGATCCCGCGACGA*C-3' (SEQ ID NO: 2), 5'-GACCGCGACTCCAG*C- 3' (SEQ ID NO: 3), with * indicating a phosphorothioate bond.
  • the PCR mix contained 27 ul H 2 0, 5 ul template DNA, 2 ul forward primer (25 uM), 2 ul reverse primer (25 uM), 4 ul MgCl 2 (50 mM), 5 ul lOx Platinum Taq buffer (Life Technologies), 4 ul dNTPs (10 mM each) and 1 ul Platinum Taq (5U/ul, Life Technologies).
  • the cycling conditions were: one cycle of 98°C for 30 s; 35 cycles of 98°C for 30 s, 40°C for 30 s, 60°C for 15 s, 72 °C for 45 s; one cycle of 72 °C for 5 min.
  • the PCR product was purified using a MinElute Purification Column (Qiagen) and end-repaired using End-IT DNA End-Repair Kit (Epicentre) as follows: 34 ul DNA, 5 ul lOx End-Repair Buffer, 5 ul dNTP Mix, 5 ul ATP, 1 ul End-Repair Enzyme Mix. The mix was incubated at room temperature for 45 minutes, and then purified using a MinElute Purification Column (Qiagen).
  • PCR products were ligated to form concatamers using the following protocol: 35 ul End- Repaired DNA product, 40 ul 2x T4 DNA ligase buffer, 5 ul T4 DNA ligase (3000 units; Enzymatics Inc.) The mix was incubated at room temperature for 4 hours, then purified using QiaQuick Purification Column (Qiagen), and quantified by absorption at 260 rrm.
  • QiaQuick Purification Column Qiagen
  • the DNA was then amplified in a PCR mix containing 51 ul dH 2 0, 20 ul 5 x Phusion buffer, 5 ul DMSO, 2 ul 10 mM dNTPs, 50 pmol Illumina forward and reverse primers, and 1 ul Hotstart Phusion enzyme (New England Biolabs) using the following cycling program: 98°C for 30 sec; 15 cycles of 98°C for 25 sec, 65°C for 30 sec, 72°C for 30 sec; and 72°C for 5 min.
  • the amplified PCR product was purified using a NucleoSpin column (Macherey Nagel, inc.) according to the manufacturer's suggested protocol except that the NT buffer was not diluted and the DNA bound to the column was eluted in 35 ul elution buffer.
  • the captured library was quantified with realtime PCR with the primers used for grafting to the Illumina sequencing chip.
  • PCR products containing codon 12 of KRAS and codon 201 of GNAS were amplified using the primers described in Fig. 10 (Table S6).
  • Each 10-ul PCR contained 200 template molecules in 5 ul of 2x Phusion Flash PCR Master Mix (New England Biolabs) and final concentrations of 0.25 uM forward and 1.5 uM reverse primers. Note that the mutant-specific probes sometimes included locked nucleic acid residues (Fig. 10 (Table S6); Exiqon).
  • cycling conditions 98°C for 2 min; 3 cycles of 98°C for 10 sec, 69°C for 15 sec, 72°C for 15 sec; 3 cycles of 98°C for 10 se , 66°C for 15 sec, 72°C for 15 sec; 3 cycles of 98°C for 10 sec, 63°C for 15 sec, 72°C for 15 sec; 41 cycles of 98°C for 10 sec, 60°C for 60 sec. Reactions were performed in at least quadruplicate and each was evaluated independently.
  • the ligation assay was based on techniques described previously, using thermotolerant DNA ligases (58-61). Each 10-ul reaction contained 2-ul of PCR product (unpurified), 1 ul of 10 x Ampligase buffer (Epicentre), 0.5 ul of Ampligase (5U/ul, Epicentre), anchoring primer (final concentration 2 uM), WT-specific primer (final concentration 0.1 uM), and mutant-specific primer (final concentration 0.025 uM). The sequences of these primers are listed in Fig. 10 (Table S6). The following cycling conditions were used: 95°C for 3 min; 35 cycles of 95°C for 10 sec, 37°C for 30 sec, 45°C for 60 sec. Five ul of each reaction was added to 5 ul of formamide and the ligation products separated on a 10% Urea-Tris-Borate-EDTA gel (Invitrogen) and imaged with an Amersham-GE Typhoon instrument (GE Healthcare).
  • oligonucleotides each 60 bp in length and in aggregate covering the exonic sequences of all 169 genes, were synthesized in parallel using phosphoramadite chemistry on a single chip synthesized by Agilent Technologies. After removal from the chip, the oligonucleotide sequences were amplified by PCR and ligated together. Multiple displacement amplification was then used to further amplify the oligonucleotides, which were then bound to a filter. Finally, the filter was used to capture complementary DNA sequences from the cyst fluids and corresponding normal samples, and the captured DNA was subjected to massively parallel sequencing.
  • the target region corresponding to the coding exons of the 169 genes encompassed 584,871 bp. These bases were redundantly sequenced, with 902 ⁇ 41 1 (mean ⁇ 1 SD) fold-coverage in the 38 samples sequenced (19 IPMN cyst fluids plus 19 matched DNA samples from normal tissues of the same patients). This coverage allowed us to confidently detect somatic mutations present in >5% of the template molecules.
  • GNAS is a well-known oncogene that is mutated in pituitary and other uncommon tumor types (16-19). However, such mutations have rarely been reported in common epithelial tumors (20-22). In pituitary tumors, mutations cluster at two positions - codons 201 and 227 (16, 19). This clustering provides extraordinary opportunities for diagnosis, similar to that of KRAS.
  • KRAS mutations have facilitated the design of assays to detect mutations in tumors of colorectal cancer patients eligible for therapy with antibodies to EGFR (23). All twelve KRAS mutations identified through massively parallel sequencing of cyst fluids were at codon 12, resulting in a G12D, G12V, or G12R amino acid change. KRAS mutations at codon 12 have previously been identified in the vast majority of PDAs as well as in 40 to 60% of IPMNs (24-29). GNAS mutations have not previously been identified in pancreatic cysts or in PDAs.
  • GNAS as well as KRAS mutations were present in each of the three major histologic types of IPMNs - intestinal, pancreatobiliary, and gastric. However, the prevalence of the mutations varied across the histological types (P ⁇ 0.01 for both KRAS and GNAS). GNAS mutations were most prevalent in the intestinal subtype (100%), KRAS mutations had the highest frequency (100%) in the pancreatobiliary subtype and had the lowest frequency (42%) in the intestinal subtype (Table 1).
  • KRAS G12D, G12V, and G12R mutations were found in 43%, 39%, and 13% of IPMNs, respectively (Fig. 6 (Table S2)).
  • a small fraction (11%) of the IPMNs contained two different KRAS mutations and 2% contained three different mutations.
  • GNAS R201C and GNAS K201U mutations were present in 39% and 32% of the IPMNs, respectively, and 4% of the IPMNs had both mutations (Fig. 6 (Table S2)). More than one mutation in KRAS in IPMNs has been observed in prior studies of IPMNs (31-33) and the multiple KRAS and GNAS mutations are suggestive of a polyclonal origin of the tumor.
  • IPMNs are often multilocular or multifocal in nature, looking much like a bunch of grapes (Fig. 4A) (36).
  • Fig. 4A bunch of grapes
  • cyst fluid we microdissected the walls from individual locules of each of ten IPMNs from whom cyst fluid was available (example in Fig. 4B and C).
  • the individual locule walls generally appeared to be monoclonal, as more than one KRAS mutation was only found in one (4.5%) of the 22 locules examined.
  • the KRAS mutational status of the PDA was consistent with that of the associated IPMN in the same seven cases.
  • the KRAS and GNAS mutations identified in the neoplastic cells of the IPMN were not found in the associated PDA, suggesting that this invasive cancer arose from a separate precursor lesion (Fig. 9 (Table S5)).
  • KRAS mutations were found commonly in both types of PDAs, there was a dramatic difference between the prevalence of GNAS mutations in PDAs associated with IPMNs (7 of 8) vs. that in PDAs unassociated with IPMNs (0 of 116; pO.001, Fisher's Exact Test).
  • Granulosa Cell Tumors A New Prognostic Factor? Journal of Clinical Endocrinology & Metabolism 91 , 1842-1847 (2006).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Pour découvrir la pathogenèse de ces lésions, nous avons purifié l'ADN provenant de liquides kystiques correspondant à une tumeur intracanalaire papillaire mucineuse du pancréas (TIPMP) prélevés chez 19 patients et nous avons recherché des mutations susceptibles d'avoir touché 169 gènes généralement altérés en cas de cancer chez l'homme. Nous avons identifié des mutations récurrentes au niveau du codon 201 du gène GNAS. Nous avons découvert que des mutations affectant le gène GNAS étaient présentes dans 66 % des cas de TIPMP et que des mutations des gènes KRAS ou GNAS pouvaient être identifiées dans 96 % des cas. Dans huit cas, nous avons pu étudier des adénocarcinomes invasifs s'étant développés en association avec des TIPMP associées à des mutations du gène GNAS. Dans sept de ces huit cas, les mutations du gène GNAS observées au niveau des TIPMP ont également pu être détectées dans la lésion invasive. Nous n'avons pas trouvé de mutations du gène GNAS dans les autres types de tumeurs kystiques du pancréas, pas plus que dans les adénocarcinomes invasifs non associés à une TIPMP. Ces données suggèrent que les mutations du gène GNAS peuvent apporter des informations utiles au diagnostic et à la prise en charge de patients souffrant de kystes pancréatiques.
EP12802288.6A 2011-06-23 2012-06-22 Mutations observées en cas de tumeurs pancréatiques Active EP2723896B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500479P 2011-06-23 2011-06-23
PCT/US2012/043783 WO2012178034A2 (fr) 2011-06-23 2012-06-22 Mutations observées en cas de tumeurs pancréatiques

Publications (3)

Publication Number Publication Date
EP2723896A2 true EP2723896A2 (fr) 2014-04-30
EP2723896A4 EP2723896A4 (fr) 2015-02-18
EP2723896B1 EP2723896B1 (fr) 2017-03-01

Family

ID=47423237

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12802288.6A Active EP2723896B1 (fr) 2011-06-23 2012-06-22 Mutations observées en cas de tumeurs pancréatiques

Country Status (3)

Country Link
US (1) US9976184B2 (fr)
EP (1) EP2723896B1 (fr)
WO (1) WO2012178034A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3853383A1 (fr) * 2018-09-19 2021-07-28 Bluestar Genomics, Inc. Profils d'hydroxyméthylation d'adn acellulaires dans l'évaluation de lésions pancréatiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147936A1 (en) 2003-02-19 2006-07-06 Ulrich Frey Use of a gene mutation in the human gnas gene for predicting risks of diseases, courses of the disease and for predicting the response to disease therapies
CA2584723A1 (fr) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Amplifiabilite renforcee d'echantillons minimes de tissus traites au fixatif, echantillons cytologiques minimes colores, et autres sources minimes d'adn
US20120115131A1 (en) 2007-05-31 2012-05-10 Yale University Genetic lesion associated with cancer
US20120231480A1 (en) 2009-08-27 2012-09-13 Indiana University Research & Technology Corporation Materials and methods for the differential diagnosis of pacreatic lesions
JP5947392B2 (ja) 2011-11-17 2016-07-06 ザ ジョンズ ホプキンス ユニバーシティー 膵嚢胞の鑑別

Also Published As

Publication number Publication date
EP2723896A4 (fr) 2015-02-18
US9976184B2 (en) 2018-05-22
EP2723896B1 (fr) 2017-03-01
US20140179538A1 (en) 2014-06-26
WO2012178034A2 (fr) 2012-12-27
WO2012178034A3 (fr) 2013-02-28

Similar Documents

Publication Publication Date Title
US10590465B2 (en) Enrichment of nucleic acids by complementary capture
Wu et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development
CN106715723B (zh) 测定样品中pik3ca突变状态的方法
ES2691404T3 (es) Diagnóstico no invasivo del cáncer
CN107003314A (zh) 用于进行甲基化检测测定的组合物和方法
HK1223969A1 (zh) 试剂盒及其用途
CA3026809A1 (fr) Compositions et procedes de diagnostic de cancers du poumon a l'aide de profils d'expression genique
CN105969857A (zh) 非小细胞肺癌靶向治疗基因检测方法
TW202102686A (zh) 一種基因標記組合及其用途
WO2021004215A1 (fr) Réactif de détection combiné multigénique
CN112280865A (zh) 一种用于检测肝癌的试剂组合，试剂盒及其用途
CN113355415B (zh) 用于食管癌诊断或辅助诊断的检测试剂及试剂盒
TW201120449A (en) Diagnostic methods for determining prognosis of non-small-cell lung cancer
JP5865241B2 (ja) 肉腫の予後分子署名およびその使用
JP2008528001A (ja) 癌マーカーおよび検出方法
CN108823314A (zh) 一种检测血浆游离dna中rnf213突变基因的试剂盒及其应用
AU2015246009A1 (en) Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
EP4189119A1 (fr) Biomarqueurs pour diagnostiquer et surveiller le cancer du poumon
US9976184B2 (en) Mutations in pancreatic neoplasms
WO2024211731A1 (fr) Réseaux ciblant des régions de chromatine accessibles de manière différentielle à l'aide d'une réaction en chaîne par polymérase quantitative
AU2009213671A1 (en) Colon cancer associated transcript 1 (CCAT1) as a cancer marker
EP2978861B1 (fr) Des marqueurs de méthylation de l'adn sans biais définissent un défaut de champ extensif dans des tissus de la prostate histologiquement normaux associés au cancer de la prostate : nouveaux biomarqueurs pour des hommes atteints du cancer de la prostate
AU2012278784B2 (en) Semi-digital ligation assay
EP2794918A1 (fr) Diagnostic de la stéatohépatite
RU2537263C2 (ru) Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140117

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MATTHAEI, HANNO

Inventor name: HRUBAN, RALPH

Inventor name: KINZLER, KENNETH W.

Inventor name: PAPADOPOULOS, NICKOLAS

Inventor name: VOGELSTEIN, BERT

Inventor name: WU, JIAN

Inventor name: DIAZ, LUIS

Inventor name: MAITRA, ANIRBAN

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101AFI20141222BHEP

Ipc: C12N 15/11 20060101ALI20141222BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20150116

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101AFI20150109BHEP

Ipc: C12N 15/11 20060101ALI20150109BHEP

17Q First examination report despatched

Effective date: 20150924

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160909

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAITRA, ANIRBAN

Inventor name: KINZLER, KENNETH W.

Inventor name: MATTHAEI, HANNO

Inventor name: VOGELSTEIN, BERT

Inventor name: DIAZ, LUIS

Inventor name: HRUBAN, RALPH

Inventor name: PAPADOPOULOS, NICKOLAS

Inventor name: WU, JIAN

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 871418

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012029331

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170301

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 871418

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170601

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170602

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170601

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170701

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170703

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012029331

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20171204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170622

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170622

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170622

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120622

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170301

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230529

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250627

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250627

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250625

Year of fee payment: 14